July 12–16, 2021,
Delivered Digitally
LILLY FOR BETTER SCIENCE
NO TWO APPROACHES ARE THE SAME – BUT THE GOAL ALWAYS IS
A message from
Ken Custer
VP of Business Development and Lilly New Ventures
PARTNER WITH ELI LILLY AND COMPANY
Collaboration. Acceleration. Investment. We specialize in helping early innovation grow into impactful medicines.
- Lilly is dedicated to searching the globe for exciting scientific breakthroughs that have the potential to positively impact our future and ensure that we all live healthier, longer, fuller lives.
- We always start with the science. We are committed to creatively, flexibly, and efficiently building partnerships to progress the science we believe in.
- Lilly offers deep scientific and business expertise, state-of-the-art facilities, cutting edge capabilities and decades of experience developing ideas into tangible treatments.
- By connecting this with entrepreneurs who create and build transformative companies and treatments, we empower innovators to deliver medicines to patients in need.
And we have the track record to show it. Here’s some of the things we’ve been up to:
AveXis name recognition and Zolgensma legacy hook Lilly in Jaguar's $139M series B
April 13, 2021
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
March 17, 2021
University of Glasgow Announces Research Collaboration with Lilly to Discover Potential New Drug Targets
February 15, 2021
Lilly Announces Agreement to Acquire Prevail Therapeutics
December 15, 2020
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
November 20, 2020
Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement with Lilly
June 09, 2020
Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines
March 31, 2020
Helmholtz Zentrum München allies with Eli Lilly and Company to discover new targets for pancreatic beta cell regeneration in the treatment of diabetes
October 25, 2019
Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
October 29, 2018
Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
April 04, 2018